Drug interactions with phytotherapeutics in oncology

Bibliography

• Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010;55:515-25
   PubMed Web of Science ®Google Scholar
• Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75
   PubMed Web of Science ®Google Scholar
• Blumenthal M, Lindstrom A, Ooyen C, Lynch ME. Herb supplement sales increase 4.5% in 2011 despite still-weak economy, herb sales continue multi-year growth. HerbalGram 2012;95:60-4
   Google Scholar
• De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004;76:1-17
   PubMed Web of Science ®Google Scholar
• Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14
   PubMed Web of Science ®Google Scholar
• Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82
   PubMed Web of Science ®Google Scholar
• Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 2012;11:187-203
   PubMed Web of Science ®Google Scholar
• Adams D, Dagenais S, Clifford T, et al. Complementary and alternative medicine use by pediatric specialty outpatients. Pediatrics 2013;131:225-32
   PubMed Web of Science ®Google Scholar
• Kelly KM. Complementary and alternative medical therapies for children with cancer. Eur J Cancer 2004;40:2041-6
   PubMed Web of Science ®Google Scholar
• Nordeng H, Bayne K, Havnen GC, Paulsen BS. Use of herbal drugs during pregnancy among 600 Norwegian women in relation to concurrent use of conventional drugs and pregnancy outcome. Complement Ther Clin Pract 2011;17:147-51
   PubMedGoogle Scholar
• Morris KT, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 2000;179:407-11
   PubMed Web of Science ®Google Scholar
• Boon H, Stewart M, Kennard MA, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000;18:2515-21
   PubMed Web of Science ®Google Scholar
• Werneke U, Earl J, Seydel C, et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-13
   PubMed Web of Science ®Google Scholar
• Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 2008;16(7):763-9
   PubMed Web of Science ®Google Scholar
• Shen J, Andersen R, Albert PS, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2002;2:8
   PubMedGoogle Scholar
• Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-52
   PubMed Web of Science ®Google Scholar
• Giveon SM, Liberman N, Klang S, Kahan E. Are people who use “natural drugs” aware of their potentially harmful side effects and reporting to family physician? Patient Educ Couns 2004;53:5-11
   PubMed Web of Science ®Google Scholar
• Humpel N, Jones SC. Gaining insight into the what, why and where of complementary and alternative medicine use by cancer patients and survivors. Eur J Cancer Care (Engl) 2006;15:362-8
   PubMed Web of Science ®Google Scholar
• Mills E, Ernst E, Singh R, et al. Health food store recommendations: implications for breast cancer patients. Breast Cancer Res 2003;5:R170-4
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004;14:1-18
   PubMedGoogle Scholar
• Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103-41
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23
   PubMed Web of Science ®Google Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-33
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715
   PubMed Web of Science ®Google Scholar
• Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. 2007. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspx [Accessed 06 September 2013]
   Google Scholar
• Drug Developement and Durg Interactions: table of Substrates, Inhibitors, and Inducers. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inVivo [Last accessed 06 September 2013]
   Google Scholar
• Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004;75:331-41
   PubMed Web of Science ®Google Scholar
• Huttunen KM, Raunio H, Rautio J. Prodrugs–from serendipity to rational design. Pharmacol Rev 2011;63:750-71
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21
   PubMed Web of Science ®Google Scholar
• Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-8
   PubMed Web of Science ®Google Scholar
• Phan VH, Moore MM, McLachlan AJ, et al. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 2009;5:243-57
   PubMed Web of Science ®Google Scholar
• Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 2006;1:119-28
   PubMedGoogle Scholar
• Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003;42:1071-88
   PubMed Web of Science ®Google Scholar
• Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003;28:203-28
   PubMed Web of Science ®Google Scholar
• Glaeser H. Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 2011;201:285-97
   PubMedGoogle Scholar
• EMEA, Guidelines on the Investigation of Bioequivalence. Doc. Ref. CPMP/EWP/QWP/1401/98 Rev. 1. London. 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003011.pdf [Last accessed 18 July 2013]
   Google Scholar
• Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30
   PubMed Web of Science ®Google Scholar
• Europäische Arzneibuchkommision. Europäisches Arzneibuch. C.H. Beck, Nördlingen; 2011
   Google Scholar
• Wurglics M, Westerhoff K, Kaunzinger A, et al. Comparison of German St. John's wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash) 2001;41:560-6
   PubMedGoogle Scholar
• Wanwimolruk S, Wong K, Wanwimolruk P. Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Metabol Drug Interact 2009;24:17-35
   PubMedGoogle Scholar
• Jänicke C, Grünwald J, Brendler T. Handbuch phytotherapie Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart; 2003
   Google Scholar
• Draves AH, Walker SE. Analysis of the hypericin and pseudohypericin content of commercially available St John's Wort preparations. Can J Clin Pharmacol 2003;10:114-18
   PubMedGoogle Scholar
• Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503
   PubMed Web of Science ®Google Scholar
• Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. Cochrane Database Syst Rev 2012;3:CD006206
   Google Scholar
• Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92
   PubMed Web of Science ®Google Scholar
• Mozaffari-Khosravi H, Hesabgar HA, Owlia MB, et al. The effect of garlic tablet on pro-inflammatory cytokines in postmenopausal osteoporotic women: a randomized controlled clinical trial. J Diet Suppl 2012;9:262-71
   PubMedGoogle Scholar
• Pittler MH, Ernst E. Clinical effectiveness of garlic (Allium sativum). Mol Nutr Food Res 2007;51:1382-5
   PubMed Web of Science ®Google Scholar
• Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 2006;136:716S-25S
   PubMed Web of Science ®Google Scholar
• Berginc K, Kristl A. The mechanisms responsible for garlic - drug interactions and their in vivo relevance. Curr Drug Metab 2013;14:90-101
   PubMed Web of Science ®Google Scholar
• Patel J, Buddha B, Dey S, et al. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004;11:262-77
   PubMedGoogle Scholar
• Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008;38:559-73
   PubMed Web of Science ®Google Scholar
• Amagase H, Petesch BL, Matsuura H, et al. Intake of garlic and its bioactive components. J Nutr 2001;131:955S-62S
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: st John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22:525-39
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72:276-87
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003;74:170-7
   PubMed Web of Science ®Google Scholar
• Cox MC, Low J, Lee J, et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-40
   PubMed Web of Science ®Google Scholar
• Mohammed Abdul MI, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008;154:1691-700
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-8
   PubMed Web of Science ®Google Scholar
• Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 2004;1:49-56
   PubMed Web of Science ®Google Scholar
• Vellas B, Coley N, Ousset PJ, GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012;11:851-9
   PubMed Web of Science ®Google Scholar
• Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000;81:668-78
   PubMed Web of Science ®Google Scholar
• Hermann R, vonRichter O. Ginkgo biloba. Dtsch Apoth Ztg 2013;24:2454-60
   Google Scholar
• Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007;100:23-30
   PubMed Web of Science ®Google Scholar
• He N, Cai HB, Xie HG, et al. Induction of cyp3a in primary cultures of human hepatocytes by ginkgolides a and B. Clin Exp Pharmacol Physiol 2007;34:632-5
   PubMed Web of Science ®Google Scholar
• Mauri P, Simonetti P, Gardana C, et al. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom 2001;15:929-34
   PubMed Web of Science ®Google Scholar
• Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004;318:1072-8
   PubMed Web of Science ®Google Scholar
• Etheridge AS, Black SR, Patel PR, et al. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007;73:731-41
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 2012;68:553-60
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Kaneda A, et al. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004;44:538-42
   PubMed Web of Science ®Google Scholar
• Vardy J, Dhillon HM, Clarke SJ, et al. Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springerplus 2013;2:126
   Google Scholar
• Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841-50
   PubMedGoogle Scholar
• Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother 2009;43:726-31
   PubMed Web of Science ®Google Scholar
• Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med 2005;20:657-61
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-32
   PubMed Web of Science ®Google Scholar
• Kellermann AJ, Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011;31:490-502
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, von Moltke LL, Luo Y, et al. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006;46:214-21
   PubMed Web of Science ®Google Scholar
• Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46:1290-8
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008;24:591-9
   PubMed Web of Science ®Google Scholar
• Fan L, Tao GY, Wang G, et al. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 2009;43:944-9
   PubMed Web of Science ®Google Scholar
• Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003;10:247-51
   PubMedGoogle Scholar
• Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-93
   PubMed Web of Science ®Google Scholar
• Karmazyn M, Moey M, Gan XT. Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011;71:1989-2008
   PubMed Web of Science ®Google Scholar
• Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician 2003;68:1539-42
   PubMed Web of Science ®Google Scholar
• Henderson GL, Harkey MR, Gershwin ME, et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999;65:PL209-14
   PubMed Web of Science ®Google Scholar
• He N, Xie HG, Collins X, et al. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol 2006;33:813-15
   PubMed Web of Science ®Google Scholar
• Hao M, Ba Q, Yin J, et al. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet 2011;26:201-5
   PubMed Web of Science ®Google Scholar
• Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol 2012;52:932-9
   PubMed Web of Science ®Google Scholar
• Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003;43:643-8
   PubMed Web of Science ®Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9
   PubMed Web of Science ®Google Scholar
• Beckert BW, Concannon MJ, Henry SL, et al. The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007;120:2044-50
   PubMed Web of Science ®Google Scholar
• Lee SH, Ahn YM, Ahn SY, et al. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med 2008;14:715-21
   PubMed Web of Science ®Google Scholar
• Yuan CS, Wei G, Dey L, et al. Brief communication: american ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med 2004;141:23-7
   PubMed Web of Science ®Google Scholar
• Lee LS, Wise SD, Chan C, et al. Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol 2008;48:599-609
   PubMed Web of Science ®Google Scholar
• Barrett B, Brown R, Rakel D, et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med 2010;153:769-77
   PubMed Web of Science ®Google Scholar
• Schapowal A, Berger D, Klein P, Suter A. Echinacea/sage or chlorhexidine/lidocaine for treating acute sore throats: a randomized double-blind trial. Eur J Med Res 2009;14:406-12
   PubMed Web of Science ®Google Scholar
• Modarai M, Gertsch J, Suter A, et al. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007;59:567-73
   PubMed Web of Science ®Google Scholar
• Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004;75:89-100
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Hubbard MA, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755-63
   PubMed Web of Science ®Google Scholar
• Abdul MI, Jiang X, Williams KM, et al. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 2010;69:508-15
   PubMed Web of Science ®Google Scholar
• Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010;30:797-805
   PubMed Web of Science ®Google Scholar
• Moltó J, Valle M, Miranda C, et al. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011;55:326-30
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008;52:772-9
   PubMed Web of Science ®Google Scholar
• Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009;8:208-27
   PubMed Web of Science ®Google Scholar
• Butterweck V, Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007;157:356-61
   PubMedGoogle Scholar
• Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006;62:29-36
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9
   PubMed Web of Science ®Google Scholar
• Xu H, Williams KM, Liauw WS, et al. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008;153:1579-86
   PubMed Web of Science ®Google Scholar
• Bell EC, Ravis WR, Lloyd KB, Stokes TJ. Effects of St. John's wort supplementation on ibuprofen pharmacokinetics. Ann Pharmacother 2007;41:229-34
   PubMed Web of Science ®Google Scholar
• Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402-8
   PubMed Web of Science ®Google Scholar
• Will-Shahab L, Bauer S, Kunter U, et al. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009;65:287-94
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011;51:75-83
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1067-81
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8
   PubMed Web of Science ®Google Scholar
• Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2000;68:637-46
   PubMed Web of Science ®Google Scholar
• Martin-Facklam M, Rieger K, Riedel KD, et al. Undeclared exposure to St. John's Wort in hospitalized patients. Br J Clin Pharmacol 2004;58:437-41
   PubMed Web of Science ®Google Scholar
• Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006;11:732-41
   PubMed Web of Science ®Google Scholar
• Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995;333:803-4
   PubMed Web of Science ®Google Scholar
• Ries CA, Sahud MA. Agranulocytosis caused by Chinese herbal medicines. Dangers of medications containing aminopyrine and phenylbutazone. JAMA 1975;231:352-5
   PubMed Web of Science ®Google Scholar
• Offerhaus L, Dukes MN, Smits HM. "Herbal" medicines and rheumatoid arthritis. Br Med J 1979;2:668
   PubMedGoogle Scholar
• Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 1997;37:344-50
   PubMed Web of Science ®Google Scholar
• Ko RJ. Adulterants in Asian patent medicines. N Engl J Med 1998;339:847
   PubMed Web of Science ®Google Scholar
• Keane FM, Munn SE, du Vivier AW, et al. Analysis of Chinese herbal creams prescribed for dermatological conditions. BMJ 1999;318:563-4
   PubMed Web of Science ®Google Scholar
• Bircher AJ, Niederer M, Hohl CH, Surber CH. Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol 2002;146:531-2
   PubMed Web of Science ®Google Scholar
• Lord GM, Tagore R, Cook T, et al. Nephropathy caused by Chinese herbs in the UK. Lancet 1999;354:481-2
   PubMed Web of Science ®Google Scholar
• Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686-92
   PubMed Web of Science ®Google Scholar
• Nortier JL, Vanherweghem JL. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). Toxicology 2002;181-182:577-80
   PubMed Web of Science ®Google Scholar
• Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009;12:46-78
   PubMed Web of Science ®Google Scholar
• Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 2011;201:29-104
   PubMedGoogle Scholar
• König J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb Exp Pharmacol 2011;201:1-28
   PubMedGoogle Scholar
• Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 2008;98:857-62
   PubMed Web of Science ®Google Scholar
• Meyer zu Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol 2011;201:325-71
   PubMedGoogle Scholar
• Zhou SF, Wang LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008;15:1981-2039
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011;201:105-67
   PubMedGoogle Scholar